StockData

Gelteq vs Lexaria Bioscience

GELS and LEXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GELS and LEXX compare

Lexaria Bioscience scores higher on the StockData Score (8 against 0 for Gelteq), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGELSLEXX
Size and price
Market cap–$110M
Share price$0.380$4.44
Change, 1 year−64.1%−74.0%
Change, 5 years–−94.7%
Beta (5Y)2.500.82
Employees–134
StockData Score
Total score08 (better)
Valuation score00
Growth score02 (better)
Performance score00
Health score06 (better)
Dividend score00
Valuation
P/S–567×
P/B–23.2×
FCF yield–−6.8%
Growth
Revenue growth (TTM)–−68.5%
Revenue growth, 5Y average–17.5%
Profitability
Gross margin30.3%100% (better)
Operating margin−3318% (better)−3973%
Net margin–−3986%
FCF margin−3335% (better)−3849%
Return on equity–−150%
Return on invested capital–−602%
Financial health
Debt / equity–0.00
Interest coverage−2.8×–
Current ratio0.0910.60 (better)
Altman Z-score–126.66
Piotroski F-score–2
Dividends and buybacks
Buyback yield–−5.9%
Shareholder yield–−5.9%
Ownership
Held by insiders14.0%3.0%
Short interest, % of float–0.90%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.